Navigation Links
Cell Therapeutics, Inc.'s (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
Date:9/8/2009

SEATTLE, Sept. 9 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) management will present at the Rodman & Renshaw 11th Annual Healthcare Conference on Wednesday, September 9th at 11:40 AM Eastern in the Spellman Salon (5th Floor) at the New York Palace Hotel.

The conference will also be webcast live with slides and available for replay after the presentation. The webcast can be accessed at www.celltherapeutics.com.

                Rodman & Renshaw 11th Annual Healthcare Conference
                     CTI Presentation: Wednesday, September 9
                        11:40 AM ET/5:40 PM CET/8:40 AM PT
              Audio webcast with slides at www.celltherapeutics.com

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    F: 206.272.4434
    E: media@ctiseattle.com
    www.celltherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.272.4345
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.celltherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Oxygen Biotherapeutics, Inc. to Begin Oxycyte(R) Phase II Clinical Trials in Switzerland
2. Rx for Africa, Inc. and Zirus, Inc. Create Joint Venture, ZiRx Therapeutics, Ltd.
3. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 6
4. Cell Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Warrants
5. Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement
6. Cell Therapeutics, Inc. Announces Public Offering of Common Stock and Warrants
7. Oxygen Biotherapeutics, Inc. Announces Closing of Offer to Acquire Warrants
8. QuikByte Software, Inc. and Sorrento Therapeutics, Inc. Announce Merger Agreement
9. European Medicines Agency (EMEA) Approves Cell Therapeutics, Inc.s September Meeting Request to Discuss OPAXIO(TM) Marketing Authorization Application
10. Oxygen Biotherapeutics, Inc. Announces Private Placement Financing Agreement and Offer to Acquire Warrants
11. Prospect Therapeutics, Inc.s GCS-100 Exhibits a Low Toxicity Profile in Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... ... enough sleep affects much more than energy – it also has mental and physical benefits. ... motor reaction time, which can increase the risk of having a car accident. , ... the NSF to help you sleep better and feel better:, , ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... http://www.wiredlifesolutions.com , “Computers are everywhere and they’re here to stay,” said ... Global Climate Change and Your Health on Voice America sponsored by Nature’s Tears® ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The ... board members and officers for 2017-2018. The annual board election process has been in ... a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... Harbor, Md. (PRWEB) , ... April 28, 2017 ... ... Care Association of America (UCAOA) and College of Urgent Care Medicine will host ... 2017 workshops, sessions and speakers will help those in the industry adapt to ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
Breaking Medicine Technology: